2025-07-15 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX), incorporating all the data points you've provided.  The report is structured to provide a clear picture of the company's performance and outlook.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

**1. Relative Performance**

*   **Ticker:** RXRX
*   **Company Description:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover, develop, and commercialize novel medicines.

*   **Key Performance Metrics:**
    *   RXRX Cumulative Return: -51.14%
    *   S&P 500 (VOO) Cumulative Return: 34.95%
    *   Absolute Divergence: -86.09%
    *   Divergence Range: (min: -88.1, max: 35.8)
    *   Relative Divergence: 4.6

    **Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period examined.  The relative divergence of 4.6 indicates that RXRX's underperformance is near the extreme end of its historical range compared to the S&P 500.

*   **Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha  | Beta | Cap(B) |
| :----------- | :--- | :--- | :----- | :--- | :----- |
| 2021-2023  | 5.0% | 73.6% | -1.0%  | -0.1 | 4.3  |
| 2022-2024  | 0.0% | 73.6% | -25.0% | 0.1  | 2.9  |
| 2023-2025  | 0.0% | 73.6% | -47.0% | 0.1  | 2.3  |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate (CAGR) has been declining over the periods presented, indicating weakening overall growth.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6%, signaling substantial potential losses for investors.
*   **Alpha:**  Alpha is consistently negative and decreasing, indicating that RXRX is significantly underperforming its benchmark on a risk-adjusted basis.
*   **Beta:** The Beta values are close to zero, suggesting that RXRX's price movements are not strongly correlated with the overall market (S&P 500).
*   **Cap:** The company's market capitalization has been decreasing over the years.

**2. Recent Price Action**

*   **Current Price:** \$5.28
*   **Previous Close:** \$5.28
*   **Change:** \$0.00
*   **5-Day Moving Average:** \$5.50
*   **20-Day Moving Average:** \$5.18
*   **60-Day Moving Average:** \$4.98

**Analysis:** The current price is slightly above the 20-day and 60-day moving averages, but below the 5-day moving average.  This suggests a potential short-term pullback after recent gains. The lack of price change from the previous close indicates a period of consolidation. Since there is no change compared to previous close, price action seems uneventful.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.3372 (Low Risk)
*   **RSI:** 57.60 (Neutral)
*   **PPO:** 0.2243 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-07-08)
*   **Delta Previous Relative Divergence (20-day):** +2.6 (Short-term Increase)
*   **Expected Return:** -536.0%

**Analysis:**

*   The MRI suggests a low-risk environment, however, it's crucial to note that MRI may not fully capture company-specific risks.
*   The RSI is in a neutral zone, indicating neither overbought nor oversold conditions.
*   The PPO is also relatively neutral.
*   The hybrid signal suggests a cautious 'buy' signal, with a low cash ratio of 0%.
*   The positive change in relative divergence over the past 20 days hints at short-term positive momentum, but it's essential to consider this in the context of the significantly negative overall divergence.
*   The extremely negative expected return indicates a very pessimistic long-term outlook relative to the S&P 500.

**4. Recent News & Significant Events**

*   **[2025-07-12]:** Business developments, regulatory changes, or market events.
*   **[2025-07-14]:** Analyst discussions on performance, industry trends, and global economic factors.
*   **[2025-07-13]:** Stock volatility due to news, earnings reports, or executive actions.
*   **[2025-07-11]:** Market expert advice to monitor news and company announcements for risks and opportunities.

**Analysis:** Recent news indicates potential significant events impacting RXRX, contributing to volatility and necessitating close monitoring.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
| :--------- | :----- | :--------- |
| 2025-05-05 | -0.50  | 0.01 B$    |
| 2024-11-06 | -0.34  | 0.03 B$    |
| 2024-08-08 | -0.40  | 0.01 B$    |
| 2024-05-09 | -0.39  | 0.01 B$    |
| 2025-05-05 | -0.39  | 0.01 B$    |

**Analysis:** The company consistently reports negative EPS, and revenue generation is relatively low. This indicates ongoing losses and limited revenue growth, raising concerns about the company's financial sustainability.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-03-31 | \$0.01B | -47.31%       |
| 2024-12-31 | \$0.00B | -183.62%      |
| 2024-09-30 | \$0.03B | 53.69%        |
| 2024-06-30 | \$0.01B | 36.14%        |
| 2024-03-31 | \$0.01B | 17.23%        |

Capital and Profitability:

| Quarter    | Equity  | ROE       |
| :--------- | :------ | :-------- |
| 2025-03-31 | \$0.93B | -21.68%   |
| 2024-12-31 | \$1.03B | -17.29%   |
| 2024-09-30 | \$0.52B | -18.27%   |
| 2024-06-30 | \$0.58B | -16.69%   |
| 2024-03-31 | \$0.40B | -22.78%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is generally low. While some quarters show positive profit margins, others are deeply negative, indicating inconsistent profitability.
*   **Capital and Profitability:** Equity levels fluctuate. ROE is consistently negative, further reinforcing the concern about the company's ability to generate returns for shareholders.

**7. Overall Assessment**

Recursion Pharmaceuticals Inc. (RXRX) presents a high-risk investment profile.  The company has significantly underperformed the S&P 500, exhibits high volatility, and reports consistent losses. Recent positive momentum in relative divergence should be interpreted cautiously against the backdrop of long-term underperformance and negative expected returns. The recent news events suggest potential catalysts, but also uncertainty. The consistent negative EPS, low revenue, and negative ROE point to significant financial challenges.

**Recommendation:** Due to the high level of risk and poor financial performance, a cautious approach is warranted. Investors should closely monitor company announcements, news, and financial reports before considering an investment. This stock is not recommended for risk-averse investors.
